A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as clinically measured by HCV RNA-or HCV-recognizing antibodies. The population who exhibit this trait is termed exposed uninfected (EU). Increasing evidence has refined characterization of these individuals, distinct from those who become infected but spontaneously clear HCV. Study of the EU population is highly pertinent for the discovery of antiviral mechanisms of resistance that can reveal antiviral therapeutic strategies. This review provides an overview of similarities and differences of the EU population relative to spontaneous resolvers and the majority whom develop chronic HCV infection, and focusses on possible mechanisms of resistance including innate and adaptive immunity, genetics and lipid interactions. There is evidence that a small proportion of PWIDs remain HCV RNA and anti-HCV negative despite their history of repeated exposure to HCV through sharing of injecting needles and other paraphernalia.
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| INTRODUCTION

Hepatitis C virus (HCV) infection is
1 a major global public health problem that can result in cirrhosis, liver cancer and death with estimates of prevalence of antibodies against HCV (anti-HCV) ranging between 1.3% and 2.1%. 2 Injection drug use is the dominant risk factor for HCV transmission in economically developed countries. Longer duration of injecting drug use is associated with increased prevalence of HCV infection (64%-94% HCV anti-HCV positive). There is evidence that a small proportion of PWIDs remain HCV RNA and anti-HCV negative despite their history of repeated exposure to HCV through sharing of injecting needles and other paraphernalia.
Our group and others have previously characterized this cohort of PWIDs defining them as "exposed uninfected" (EU). [6] [7] [8] [9] [10] The phenotype of repeated exposure to HCV without the development of infection is of considerable interest because it suggests these individuals are in some way resistant to HCV infection. This review considers the phenotypic definitions of the EU cohort and the distinct immunological and genetic features that characterize the EU group to gain insights into possible mechanisms of HCV resistance.
| DIFFERENCES BETWEEN HCV EXPOSED UNINFECTED (EU), SPONTANEOUS RESOLVERS (SR) AND THOSE WITH CHRONIC HCV (CHCV)
Parenteral HCV exposure results in one of three different outcomes:
the majority of individuals develop chronic HCV infection (CHCV) with detectable anti-HCV and persisting HCV RNA, while approximately 20% of people spontaneously resolve infection (SR) 11 with detectable anti-HCV but clearance of HCV RNA, and finally a minority, who despite similar viral exposure, remain uninfected (EU) lacking detectable anti-HCV and HCV RNA. These three outcomes can be characterized by differing immunological and genetic profiles (Table 1) .
| HCV "EXPOSED UNINFECTED" DESIGNATION
HCV exposure without infection has been described by several groups. While we have termed this cohort "exposed uninfected", 6 other groups describe a similar phenomenon in both HCV and human immunodeficiency virus (HIV) as "highly exposed seronegative (HESN)", 12 "highly exposed persistently seronegative", 13 repeatedly "exposed seronegative (ESN)". 14 For meaningful debate and understanding, there needs to be clarity about phenotypic nomenclature.
| EXPOSED UNINFECTED INDIVIDUALS REPRESENT A DISTINCT GROUP
In the absence of serological evidence for developing infection, HCV exposure can only be determined by probability based on the history 
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T A B L E 1 Immunological and genetic differences based on hepatitis C virus natural history cytokines in response to in vitro stimulation with specific antigens (in this case HCV peptides) 19 and is highly sensitive allowing for detection of as few as one cell in 100 000. 20 Cellular IFN-γ production is used as a readout of single-cell activation with individual spots representing each cytokine-secreting cell. 20 Using ELISpot up to 60% of high-risk individuals have detectable HCV-specific T-cell responses. 
| IMMUNOLOGICAL RESISTANCE TO HCV
Given the high prevalence of T-cell responses in the EU cohort, immunological mechanisms may be an important component of HCV resistance and the data suggesting differences in adaptive and innate immune responsiveness in EU compared to others are reviewed here. Partial protective immunity after spontaneous resolution of HCV infection has been reported, with lower rates of HCV reinfection than would be expected in a matched uninfected population. 28 Detectable HCV-specific T-cell responses remain for many years after spontaneous clearance, 29 but their role in providing this partial protection has not been established.
| Adaptive immune responses
| T Cells
In exposed uninfected cases up to 60% have demonstrable T-cell responses, 6 often to multiple viral antigens, but these responses are typically much weaker than those seen in SR. 
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In conclusion, while HCV-specific T-cell immunological responses do provide good evidence of viral exposure, their role in conferring any protection from infection remains unproven, which suggests that there are other mechanisms involved in resistance to HCV infection.
| B cell-and anti-HCV-mediated protection
There is growing evidence that a robust anti-envelope antibody response can contribute significantly to viral clearance in acute infection 39 with the rapid onset of anti-HCV capable of neutralizing diverse strains of HCV being associated with clearance. 40 The presence of specific anti-envelope antibodies provides further confirmation of HCV exposure in these cases and is a plausible, but as yet unproven, mechanism by which some of these subjects may have resisted HCV infection following a low-dose inoculation.
| Innate immunity
The innate immune system is the first line of defence against viral ill- There is increasing evidence to support a key role for innate immune responses in EU cases. A study looking at serum cytokine profiles in EU cases found significantly elevated levels of the pro-inflammatory innate immune cytokine interleukin-6 and chemokine interleukin-8 in EUs compared to those with chronic HCV, spontaneous resolvers or healthy controls. 46 A genetic study of the NK-cell KIR receptors identified homozygosity for KIR2DL3:HLA-C1, which is linked to a readily activated NK-cell phenotype, 47 to be associated with the resistance to HCV infection seen in EU cases. 48 Of interest, the IL-28B variant strongly associated with spontaneous resolution of HCV infection and a favourable treatment outcome was not found to be associated with these EU cases indicating that EU individuals are a distinct population from patients who spontaneously resolve HCV infection. susceptible to HLA-E-mediated inhibition. 49 The strongest evidence to date comes from a prospectively studied cohort of seronegative PWIDs in Australia. 36 This nested case-control series studied 28 previously seronegative cases who seroconverted (incident cases of HCV)
matched by demographics and risk behaviour to 28 EU subjects who remained seronegative on follow-up. Samples were assayed for NKcell phenotypes and function before and after incident HCV infection to seek correlates with ongoing resistance to HCV in those who remained uninfected. Sustained NK-cell activation was found to contribute to protection against HCV infection with significantly higher numbers of both activated and cytotoxic cells found in the EU subjects together with higher frequencies of interferon gamma (IFN-γ)-producing NK cells. In contrast, no correlation with HCV-specific T-cell responses and ongoing protection was identified.
| Other possible mechanisms of HCV resistance
| Genetic
To date, genetic studies in EU cases have been limited by the relatively small cohorts identified and reported on, so that studies have focussed on specific candidate genes. Further collaborative investigations combining different EU cohorts will be needed to undertake any appropriately powered genomewide association study.
Candidate genes include those that influence the host innate/and or adaptive immune responses as well as those encoding HCV receptor molecules.
We have previously shown an association between the variant IL-12B C allele and resistance to HCV infection in EU cases. ).
CD81 appears to be very highly conserved with no genetic alterations found in a study of EU cases, HCV-infected cases and controls.
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Studies reported on a French cohort of HIV-infected PWIDs with and without HCV infection (the HCV-negative cases were considered EU) looked at sequencing findings in 22 EU cases and found no alteration in claudin 1, 54 but did find heterozygous variants in claudin 6 and occludin in one case and two heterozygous variants in SRB-1 in another. 55 The relevance of these to resistance to HCV is unclear as detailed study
showed that the variations in claudin 6 and occludin identified did not confer resistance to HCV infection in an in vitro model. RNA, viral proteins and host apolipoprotein constituents including apoB, apoE, apoA1 and apoC. 58 Growing evidence suggests that the LVP lipid and apolipoprotein components facilitate viral attachment to host cells by binding to cellular lipoprotein receptors and that the exchangeable apoE appears to be crucial for infectivity at the attachment step and at masking envelope glycoproteins from neutralizing antibodies. 59 HCV replication takes place on lipid droplets with colocalization of core protein and nonstructural NS5A to the lipid droplet.
Production of infectious HCV is dependent on hepatocyte machinery for the export of very low density lipoproteins (VLDL). 60 Thus, evidence points towards a key role for lipid metabolism in the HCV lifecycle, and the close association with lipids and lipoproteins contributes to HCVs ability to evade the host's immune surveillance.
Given this codependency on host lipid pathways, it is plausible that any mechanism that would disrupt the LVP formation would potentially reduce the viral infectivity and influence outcome following HCV exposure.
Recently reported, but preliminary, data using lipidomics profiling demonstrated that the HCV-resistant EU phenotype was clearly distinct from HCV-susceptible individuals. 61 The role of lipids and lipid pathways in conferring HCV resistance is of interest but remains to be clarified.
| CONCLUSION
Hepatitis C virus exposure through injection drug use that does not result in infection is now well described in several countries. This EU group exhibit resistance to HCV infection. Detailed study to date sug- The accurate characterization of HCV exposed uninfected cases remains crucial to future studies and raises issues regarding the definition and confirmation of HCV exposure. There remains a need for a universally agreed definition of exposure on the basis of probability derived from risk behaviours and duration of drug use and/or evidence of immune responsiveness to HCV antigens, in order to define robust exposed uninfected cohorts to investigate pathways of HCV resistance. A collaborative effort between groups using agreed definitions for EU cases could provide sufficient case numbers to undertake appropriately powered genetic studies. A better understanding of all the factors associated with HCV resistance would be a major step forward in our understanding of the pathogenesis of this highly prevalent infection and in the search for alternative therapeutic strategies.
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